

Show this card to any healthcare professional involved in your medical care – for example, your dentist or an emergency doctor.

▼ This medicinal product is subject to additional monitoring. This will facilitate rapid collection of new safety information. Should you experience any adverse reactions, please tell your doctor or pharmacist, or you can also report them directly at: State Institute for Drug Control, pharmacovigilance department, Šrobárova 48, Praha 10, 100 41, email: farmakovigilance@sukl.cz or to AbbVie at safety-cz@abbvie.com.

Your name:

.....
Consultant's name – who prescribed RINVOQ®:

.....
Consultant's phone number:

.....
The date you started RINVOQ®:

.....
Version 1.0. Date approved October 17, 2019.
SÚKL approved in May 2020



CZ-RNQR-200004

abbvie

Patient Alert Card

Keep this card with you all the time

Safety Information about RINVOQ® ▼ (upadacitinib) for Patients

- This card contains important safety information you should be aware of – before and during treatment with RINVOQ®.
- Read the patient information leaflet (PIL) for more information. PIL is distributed in each package of the medicine. It may be also found at <http://www.olecich.cz> or by scanning the QR code at www.rinvoq.eu.

Risk of infections

RINVOQ® may make an existing infection worse or increase the chance of you getting a new infection – for example tuberculosis (TB), shingles or viral hepatitis.

Tell your doctor straight away if you notice signs of infection, such as:

- Fever, sweating, chills, weight loss, or a cough that won't go away – these may be signs of TB
- Painful skin rash with blisters – this may be a sign of shingles
- Feeling tired or short of breath – this may be a sign of pneumonia.

Vaccines – used to help prevent infections

Live vaccines (for example the influenza vaccine nasal spray) should not be given during RINVOQ® treatment, or just before starting RINVOQ® treatment.

Before being given any vaccines, talk to your doctor – they will know which vaccines you should not be given before or during treatment with RINVOQ®.

Cholesterol

Your doctor will check your cholesterol levels while you are taking RINVOQ® – this is to decide if you need to start a medicine to lower your cholesterol levels.

Contraception, pregnancy, and breast-feeding

RINVOQ® must not be taken during pregnancy.

- Use effective contraception while taking RINVOQ® – and for 4 weeks after your last dose. Talk to your doctor about effective contraception.
- Tell your doctor straight away if you wish to become pregnant, or if you become pregnant.
- Do not breast-feed while using RINVOQ®.

Blood clots in veins (DVT) or lungs (PE)

Tell your doctor straight away if you get signs of DVT or PE, such as a painful swollen leg or chest pain.